Moderna COVID-19 vaccine
 Moderna COVID-19 vaccine | |
|---|---|
funded product (en)  | |
 | |
| Bayanai | |
| Ƙaramin ɓangare na |
Rigakafin Covid-19 da RNA vaccine (en) |
| Vaccine for (en) | Koronavirus 2019 |
| Route of administration (en) |
intramuscular injection (en) |
| Mai haɓakawa |
Moderna (en) , National Institute of Allergy and Infectious Diseases (en) da Medidata Solutions (en) |
| Funder (en) |
Biomedical Advanced Research and Development Authority (en) , Coalition for Epidemic Preparedness Innovations (en) da Operation Warp Speed (en) |
| NCI Thesaurus ID (en) | C172736 |
Alurar rigakafin Moderna COVID ‑ 19, wanda aka sayar a ƙarƙashin sunan alamar Spikevax, wani maganin COVID-19 ne wanda kamfanin Amurka Moderna ya kirkira, Cibiyar Nazarin Allergy da Cututtuka ta Amurka (NIAID), da Hukumar Bincike da Ci gaba ta Biomedical. BARDA). Dangane da ikon, an ba da izini don amfani ga mutane masu shekaru da kuma 'yan watanni shida, shekaru goma sha biyu, ko shekaru goma sha takwas zuwa sama. Yana ba da kariya daga COVID-19, wanda kamuwa da cuta ta SARS-CoV-2 ke haifarwa. [1] [2]
An tsara shi don gudanar da shi a cikin allurai biyu ko uku na 0.5- mL da aka ba ta hanyar allurar ciki, da farko a cikin tsokar deltoid, a tazara na akalla kwanaki 28. [3] [4] Hukumar Lafiya ta Duniya ta ba da shawarar tazara na mako takwas tsakanin allurai don inganta inganci. An yarda da ƙarin allurai masu ƙarfafawa a wasu yankuna don kiyaye rigakafi. Gwajin gwaji na asibiti da bayanan duniya na gaske sun nuna ingancin maganin, tare da ingantaccen tasiri da aka lura da makwanni biyu bayan gudanar da kashi na biyu, yana ba da kariya ta 94% daga Covid da ingantaccen tsaro daga lokuta masu tsanani. Tasirin maganin ya shafi alƙaluma daban-daban, gami da shekaru, jima'i, da waɗanda ke da haɗarin lafiya.
Alurar rigakafin mRNA ce da ta ƙunshi mRNA (modRNA) da aka gyara na nucleoside wanda ke ɓoye furotin mai karu na SARS-CoV-2, wanda ke lullube a cikin nanoparticles na lipid . [5] A watan Agusta da Satumba 2022, nau'ikan alluran rigakafin (Moderna COVID-19 Vaccine, Bivalent) mai ɗauke da elasomeran/elasomeran 0-omicron (Spikevax Bivalent Zero/Omicron) an ba su izini don amfani azaman allurai masu haɓakawa a cikin mutane masu shekaru 18 ko sama a cikin United Kingdom, Switzerland, Australia, Kanada, [6] Tarayyar Turai, da Amurka. [7] [8] Bangaren na biyu na nau'in rigakafin bivalent da ake amfani da shi a cikin Amurka ya dogara ne akan bambancin Omicron BA.4/BA.5, yayin da kashi na biyu na nau'in rigakafin bivalent da ake amfani da shi a wasu ƙasashe ya dogara. akan bambancin Omicron BA.1. An yi nazari sosai kan tasirin maganin a kan bambance-bambancen, wanda ke nuni da matakan kariya daban-daban. Misali, a lokacin yawaitar bambance-bambancen Delta, tasiri kan kamuwa da cuta ya ɗan ragu cikin lokaci. Ana nazarin tsawon rayuwar maganin da ci gaba da kariya, tare da ci gaba da bincike da ke mai da hankali kan tsawon lokacin da zai yi tasiri, wanda har yanzu ba a tantance shi ba har zuwa sabon sabuntawa.
Bayanan aminci na maganin alurar riga kafi yana da kyau, tare da illa na gama gari ciki har da ciwon wurin allura, gajiya, da ciwon kai. Mummunan halayen kamar anaphylaxis suna da wuya sosai. Damuwa game da myocarditis, an gano su amma yawanci suna da sauƙi kuma ana iya sarrafa su. Tsarin rigakafin yana amfani da fasahar mRNA, wanda aka lullube shi a cikin nanoparticles na lipid don tabbatar da ɗaukar salon salula da amsa tsarin rigakafi.
Amfani da kiwon lafiya[gyara sashe | gyara masomin]
Ana amfani da rigakafin Moderna COVID ‑ 19 don ba da kariya daga kamuwa da cuta ta kwayar cutar SARS ‑ CoV ‑ 2 don hana COVID ‑ 19.
Ana ba da maganin ta hanyar allurar cikin tsoka a cikin tsokar deltoid na hannu. Tsarin farko ya ƙunshi allurai biyu. Hukumar Lafiya ta Duniya (WHO) ta ba da shawarar tazara na makonni takwas tsakanin allurai.[9]
Ana iya ƙara kashi na uku, na huɗu, ko na biyar a wasu ƙasashe.
Manazarta[gyara sashe | gyara masomin]
- ↑ "Moderna Spikevax COVID-19 vaccines". Health Canada. 12 September 2023. Archived from the original on 15 September 2023. Retrieved 15 September 2023.
- ↑ "TGA Provisional Approval of Moderna COVID-19 vaccine to include 12-17 years age group". Therapeutic Goods Administration (TGA). 4 September 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
- ↑ "Moderna COVID-19 Vaccine". Dosing & Administration. Infectious Diseases Society of America. 4 January 2021. Archived from the original on 20 December 2020. Retrieved 5 January 2021.
- ↑ "COVID-19 Vaccines for Moderately to Severely Immunocompromised People". U.S. Centers for Disease Control and Prevention (CDC). 13 August 2021. Archived from the original on 10 December 2021. Retrieved 13 August 2021.
- ↑ Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T (February 2021). "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine". The New England Journal of Medicine. 384 (5): 403–416. doi:10.1056/NEJMoa2035389. PMC 7787219. PMID 33378609.
- ↑ "Regulatory Decision Summary - Spikevax Bivalent". Health Canada. 1 September 2022. Archived from the original on 1 September 2022. Retrieved 1 September 2022.
- ↑ "COVID-19 Vaccine Tracker: Moderna: mRNA-1273". McGill University. Archived from the original on 1 February 2022.
- ↑ "Moderna COVID-19 Vaccine". U.S. Food and Drug Administration (FDA). 7 July 2021. Archived from the original on 23 January 2021. Retrieved 5 August 2021.
- ↑ "The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know". World Health Organization (WHO). 18 August 2022. Archived from the original on 2 September 2022. Retrieved 1 September 2022.